Applied Therapeutics has filed a patent for methods to treat genetic and metabolic disorders that affect sorbitol metabolism or cause excessive sorbitol production, such as SDH deficiency and hereditary neuropathy, using aldose reductase inhibitors. GlobalData’s report on Applied Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Applied Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData Applied Therapeutics's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.

Methods for treating genetic and metabolic disorders involving sorbitol metabolism

Source: United States Patent and Trademark Office(USPTO). Credit: Applied Therapeutics Inc

A recently filed patent (Publication Number: US20230121312A1) describes a method for treating hereditary neuropathy associated with sorbitol-dehydrogenase (SDH) deficiency. The method involves administering an aldose reductase inhibitor to a subject in need of treatment. The aldose reductase inhibitor is a compound of Formula (III). The effective amount of the inhibitor is sufficient to reduce sorbitol accumulation in the subject.

The hereditary neuropathy associated with SDH deficiency can manifest as distal hereditary motor neuropathy (dHMN) or Charcot-Marie-Tooth (CMT) disease. In the case of CMT disease, it can be further specified as CMT neuropathy type 1 (CMT-1) or CMT neuropathy type 2 (CMT-2).

The aldose reductase inhibitor used in the method can be selected from a group of compounds. The subject being treated is specified as a human, and it is mentioned that the subject may have diabetes or a complication of diabetes.

The patent also provides specific details about the chemical structure of the aldose reductase inhibitor, including the formula and various substituents. The inhibitor can be a compound of Formula (III-1) or other specific compounds.

In summary, the patent describes a method for treating hereditary neuropathy associated with SDH deficiency by administering an aldose reductase inhibitor. The inhibitor reduces sorbitol accumulation in the subject and can be selected from a group of compounds. The method can be used to treat different forms of hereditary neuropathy, including dHMN and CMT disease. The patent also provides specific details about the chemical structure of the aldose reductase inhibitor.

To know more about GlobalData’s detailed insights on Applied Therapeutics, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies